跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 285 条关于
“iRECIST”
全部
285
临床试验
249
药物
5
机构
0
资讯
31
去年
Adze Biotechnology Receives Ethics Approval for Phase I Oncolytic Immunotherapy Trial in Metastatic Melanoma
去年
Beyond Cancer Receives Approval for Phase 1b Trial of LV-UNO with Anti-PD-1 Therapy in Solid Tumors
去年
Novel Complement Factor H Antibody GT103 Shows Promise in Refractory Non-Small Cell Lung Cancer Trial
5年前
Triplet Therapy of Durvalumab, Tremelimumab, and Paclitaxel Halted in Biliary Tract Cancer Trial Due to Safety Concerns
2年前
FDA Grants Orphan Drug Designation to CF33-hNIS for Cholangiocarcinoma
8个月前
BioInvent's BI-1808 Plus Pembrolizumab Shows 24% Response Rate in Recurrent Ovarian Cancer
去年
Kineta's KVA12123 Shows Promising Clinical Activity in Advanced Solid Tumors
9个月前
Triple-Negative Breast Cancer Pipeline Expands with 170+ Emerging Therapies Across Multiple Development Phases
去年
Invikafusp Alfa Demonstrates Promising Activity in Immune Checkpoint Inhibitor-Resistant Solid Tumors
去年
Triple-Negative Breast Cancer Pipeline Expands with 170+ Emerging Therapies as Companies Advance Novel Treatment Approaches
第 1 页,共 4 页
上一页
下一页